David Wambeke - DiaMedica Therapeutics Chief Officer
| DMAC Stock | USD 4.62 0.08 1.70% |
Executive
David Wambeke is Chief Officer of DiaMedica Therapeutics
| Age | 40 |
| Address | 301 Carlson Parkway, Minneapolis, MN, United States, 55305 |
| Phone | (763) 496-5454 |
| Web | https://www.diamedica.com |
DiaMedica Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2354) % which means that it has lost $0.2354 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3518) %, meaning that it created substantial loss on money invested by shareholders. DiaMedica Therapeutics' management efficiency ratios could be used to measure how well DiaMedica Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.38. In addition to that, Return On Capital Employed is expected to decline to -0.43. At present, DiaMedica Therapeutics' Non Current Assets Total are projected to decrease significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 56.4 M, whereas Non Currrent Assets Other are forecasted to decline to (0.94).Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Alpa Parikh | Lumos Pharma | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Valerie Morisset | Eliem Therapeutics | 54 | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| RPh Young | Seres Therapeutics | 57 | |
| MD FAAP | Lumos Pharma | N/A | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Nicole Esq | HCW Biologics | N/A | |
| Eddie MBA | Lumos Pharma | N/A | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Rachael Nokes | Scpharmaceuticals | 49 | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Nishi MD | Eliem Therapeutics | N/A | |
| John PharmD | Scpharmaceuticals | N/A | |
| David Ege | Seres Therapeutics | 49 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
Management Performance
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.24 |
DiaMedica Therapeutics Leadership Team
Elected by the shareholders, the DiaMedica Therapeutics' board of directors comprises two types of representatives: DiaMedica Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DiaMedica. The board's role is to monitor DiaMedica Therapeutics' management team and ensure that shareholders' interests are well served. DiaMedica Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DiaMedica Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| MS MD, Independent Consultant | ||
| Scott CA, CFO Sec | ||
| Edward Calamai, Consulting Manufacturing | ||
| Ambarish Shah, Chief Officer | ||
| Lorianne MD, Chief Officer | ||
| Dietrich MBA, CEO President | ||
| Julie CCRP, Senior Operations | ||
| Dominic Cundari, Chief Officer | ||
| David Wambeke, Chief Officer | ||
| Scott CPA, CFO Secretary |
DiaMedica Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DiaMedica Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.24 | ||||
| Current Valuation | 151.14 M | ||||
| Shares Outstanding | 42.76 M | ||||
| Shares Owned By Insiders | 26.22 % | ||||
| Shares Owned By Institutions | 31.61 % | ||||
| Number Of Shares Shorted | 175.55 K | ||||
| Price To Earning | (3.52) X | ||||
| Price To Book | 4.19 X | ||||
| EBITDA | (19.31 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DiaMedica Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.You can also try the Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.56) | Return On Assets (0.24) | Return On Equity (0.35) |
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.